Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World hair loss drug study launches: will ritlecitinib deliver in practice?

NCT ID NCT06531109

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 21, 2026 · Updated 5 times

Summary

This study follows 850 people with alopecia areata who are taking the approved drug ritlecitinib in real-world clinics. Researchers will measure hair regrowth using the SALT score over 24 weeks. The goal is to see how well the drug works outside of controlled trials, in everyday patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 450 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population eligible for enrollment includes any adult and adolescent patients aged ≥12 years diagnosed with AA who receive at least one dose of ritlecitinib and satisfy the inclusion and exclusion criteria. The study will be open for enrollment for approximately 12 months after the first patient has been enrolled. Depending on the observed enrollment rate, the enrollment period and number of sites may be reassessed and revised during the study. It will be allowed to enroll patients with previous use of topical JAK inhibitors only if there was at least a 4-week wash-out period prior to Baseline Visit

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male and female patients aged \>12 years at baseline. 2. Patients with diagnosis of alopecia areata confirmed by a certified dermatologist, who are prescribed ritlecitinib as per the product label independently of the decision to enroll a patient in this study. 3. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Following receipt of oral and written information about the trial, the adolescent (depending on local institutional review board/independent ethics committee requirements) must provide assent, and one or both (according to local regulations) parents or guardians of the child must provide signed informed consent before any study-related activity is carried out. 4. Patients, who in the opinion of the investigator, are willing and able to comply with regular clinic visits as per standard practice at the site and agree to complete PRO questionnaires and other patient completed questions. Exclusion Criteria: 1. Diagnosed with other types of alopecia or other diseases that can cause hair loss (including, but not limited to known androgenetic alopecia, traction and scarring alopecia, telogen effluvium). 2. Diagnosed with other scalp diseases that may impact AA assessment (e.g., scalp psoriasis, dermatitis, etc.) or other active systemic diseases that may cause hair loss (e.g., lupus erythematosus, thyroiditis, systemic sclerosis, lichen planus, etc.). that could interfere with assessment of hair loss/regrowth. 3. Patients previously treated with ritlecitinib or other JAK inhibitors. 4. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia areata are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia areata

Contacts and locations

Locations

  • A.O.U.C Policlinico de Bari

    Bari, BA, 70124, Italy

  • AO G. Rodolico - San Marco di Catania UOC DERMATOLOGIA

    Catania, CATANIA, 95123, Italy

  • Beijing Tongren Hospital

    Beijing, 100006, China

  • Brigham & Women's Hospital/Harvard Medical School

    Boston, Massachusetts, 02115, United States

  • C2 Research Center

    Montgomery, Alabama, 36117, United States

  • CENTER FOR DERMATOLOGY CLINICAL RESEARCH, Inc

    Fremont, California, 94538, United States

  • CHU de CAEN

    Caen, 14033, France

  • CHU de Grenoble Alpes

    La Tronche, 38700, France

  • CHU de Rennes Hôpital Pontchaillou

    Rennes, 35000, France

  • Centre Sabouraud

    Paris, Île-de-France Region, 75010, France

  • Ch Victor Dupouy

    Argenteuil, 95100, France

  • Chelsea and Westminster NHS Foundation Trust

    London, London, SW10 9NH, United Kingdom

  • Chu Dijon Bourgogne

    Dijon, 21000, France

  • Cura Clinical Research

    Oxnard, California, 93030, United States

  • Dermatology Hospital of Southern Medical University

    Guangzhou, 510091, China

  • Dermatology of Boca

    Boca Raton, Florida, 33431, United States

  • Epiphany Dermatology

    Southlake, Texas, 76092, United States

  • Frontier Dermatology

    Mill Creek, Washington, 98012, United States

  • Gloucestershire Hospitals NHS Foundation Trust

    Gloucester, GLOUCESTERSHIRE, GL13PX, United Kingdom

  • Goodlettsville Dermatology Research

    Goodlettsville, Tennessee, 37072, United States

  • Hamamatsu University Hospital

    Hamamatsu, Shizuoka, 431-3192, Japan

  • Hickory Dermatology Research Center

    Hickory, North Carolina, 28602, United States

  • Hospital of the University of Occupational and Environmental Health

    Kitakyushu-shi, Fukuoka, 807-8556, Japan

  • Huashan Hospital Affiliated to Fudan University

    Shanghai, 200040, China

  • Hôpital Larrey

    Toulouse, 31059, France

  • Hôpital Saint Vincent de Paul

    Lille, 59000, France

  • Irccs, Aoubo, Policlinico S.Orsola

    Bologna, BOLOGNA, 40138, Italy

  • Istituto clinico Humanitas

    Rozzano, Milan, 20089, Italy

  • Juntendo University Hospital

    Bunkyo-ku, Tokyo, 113-8431, Japan

  • Kindred Hair and Skin Center

    Marriottsville, Maryland, 21104, United States

  • Kurume University Hospital

    Kurume-shi, Fukuoka, 830-0011, Japan

  • London North West University Healthcare Trust

    London, NW10 7NS, United Kingdom

  • Michigan Dermatology Institute

    Waterford, Michigan, 48328, United States

  • NHS Fife

    Dunfermline, FIFE, KY120SU, United Kingdom

  • NHS Greater Glasgow and Clyde

    Glasgow, G4 0SF, United Kingdom

  • NW Dermatology Institute

    Portland, Oregon, 97210, United States

  • Nagomi Dermatology Clinic

    Ebina, Kanagawa, 243-0432, Japan

  • Niigata University Medical & Dental Hospital

    Niigata, Niigata, 951-8520, Japan

  • Oakland Hills Dermatology

    Auburn Hills, Michigan, 48326, United States

  • Osaka Metropolitan University Hospital

    Osaka, Osaka, 545-0051, Japan

  • Pediatric Skin Research,LLC

    Coral Gables, Florida, 33146, United States

  • Peking University First Hospital

    Beijing, 100034, China

  • Peking University People's Hospital

    Beijing, 100044, China

  • Policlinico Tor Vergata

    Rome, ROME, 00133, Italy

  • Policlinico Umberto I

    Roma, 00161, Italy

  • Rao Dermatology

    Fresno, California, 93720, United States

  • Raven Clinical Reseach

    Fairfax, Virginia, 22033, United States

  • Raven Clinical Reseach

    McLean, Virginia, 22102, United States

  • Raven Clinical Reseach

    Burlington, Wisconsin, 53105, United States

  • Rouen University Hospital

    Rouen, 76000, France

  • Royal United Hospital Bath

    Bath, BA1 3NG, United Kingdom

  • Shanghai Skin Disease Hospital

    Shanghai, 200443, China

  • Skin Research of South Florida LLC

    Miami, Florida, 33173, United States

  • Southern California Clinical Research

    Santa Ana, California, 92701, United States

  • Stanford

    Redwood City, California, 94063, United States

  • Suncoast Skin Solutions

    Jacksonville, Florida, 32256, United States

  • Teikyo University Hospital

    Itabashi-Ku, Tokyo, 173-8606, Japan

  • The Fist Hospital of Jilin Province

    Changchun, 130021, China

  • Tohoku University Hospital

    Sendai, Miyagi, 908-8574, Japan

  • Tokyo Medical University Hospital

    Shinjuku-Ku, Tokyo, 160-0023, Japan

  • Twin Cities Dermatology Center

    Minneapolis, Minnesota, 55416, United States

  • UPMC

    Pittsburgh, Pennsylvania, 15213, United States

  • University Hospitals Sussex

    Brighton, EAST SUSSEX, BN2 3EW, United Kingdom

  • University hospital of Bordeaux

    Bordeaux, New Aquitaine, 33000, France

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35233, United States

  • University of Iowa Health Care

    Iowa City, Iowa, 52242, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

  • Whipps Cross (Barts Health)

    London, E11 1NR, United Kingdom

  • Xiangya Hospital, Central South University

    Changsha, 410028, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.